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Sir,
At first, we would like to thank you for giving us the opportunity
to reply to this letter. It may be worth reminding that our study
was aimed at gaining insight, from only immunohistochemical
data, into the potential impact of several targets such as EGFR, Her
2, p53, VEGF and ckit in a large and homogenous series of patients
(107) with oesophageal squamous cell carcinoma. Our experiments
showed a potential impact of EGFR status, and HER2 was found to
be overexpressed by only 2.8% of the tumours (Gibault et al, 2005).
Before replying to the letter by Khan, it sounds us worth (i)
recalling that there is a consensus among the scientific community
about the difficulty of comparing data relative to the assessment of
angiogenesis by immunohistochemistry (Vermeulen et al, 2002)
and (ii) indicating that our bibliography section did not refer to
the two very interesting and recent papers by Mimura et al
(2005a,b) only because our manuscript had been submitted and
accepted before the publication of both articles.
The remarks by Khan and co-workers are focused on the low
rate reported by our team and on the potential role of HER2 in
squamous cell carcinoma of the oesophagus. We totally agree
with them about the fact that several analyses of HER2 carried out
by immunohistochemistry or other methods (Shiga et al, 1993;
Hardwick et al, 1997; Tanaka et al, 1997; Friess et al, 1999; Wang
et al, 1999; Akatmatsu et al, 2003; Miyazono et al, 2004; Mimura
et al, 2005a,b; Sato et al, 2005; Sunpaweravong et al, 2005) have all
found rates of overexpression greater than 2.8%. To our opinion,
the differences observed between these different studies have
several origins: the first of them, as clearly said by Khan and co-
workers is the high heterogeneity in the methodologies used in
the collection of studies cited by these authors. For example, Friess
studied adenocarcinoma and squamous cell carcinoma and used
an antibody and a semiquantitative procedure both different from
ours (Friess et al, 1999). Among the available methods, the Dako
Herceptest for immunohistochemical assay is considered as the
most reliable one for the detection of a positive HER-2 status; this
consideration drove us to use it and evaluate the staining as
described by Penault-Llorca et al (2002). Concerning Mimura and
co-workers, in addition to immunochemistry they performed a
Her2 gene amplification with the aim to optimise their search for
HER2 expression. However, by a careful reading of their paper
in Clinical Cancer Research (Mimura et al, 2005a) one learns
that, after the study of squamous cell lines, they analysed Her-2
expression in freshly isolated tumours (primary tumour and
malignant pleural infusion from two patients; both samples were
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in flow cytometric analysis. In the second study (Mimura et al,
2005b) published in the British Journal of Cancer, they evaluated
only HER2 in a homogenous series (66 cases) of squamous cell
carcinoma of the oesophagus treated by surgery; one should note
that, despite the lower number of cases under study, these
investigations and ours can be compared. Among their cohort of
patients, only three of them denoted (3þ) were identified by
immunochemistry as being positive; six others, denoted (2þ),
were considered as positive cases. When they compared the HER2
status between primary and metastatic lymph nodes, they clearly
found a strong correlation, but only in the three HER2 (3þ) (4.5%
of the cases). FISH analysis revealed a gene amplification in the
three strongly positive cases, that is (3þ), in three out of the six
samples denoted (2þ) and in one out of the 11 weak positive
patients termed (1þ). To our knowledge, this study is the only
report describing HER2 status in oesophageal neoplasms from
results of the two FDA-approved tests. The finding that one patient
with herceptest 1þ was positive for gene amplification suggests an
underestimation of the rate of HER2-positive cases by this test.
Ongoing experiments within our laboratory are focused on a
FISH analysis of our cohort of 126 patients. It should allow us to
get data comparable with those reported by Mimura about 66
cases.
As we also wonder about the impact of cultural habits, ethnic
differences between populations of the different continents, it
would be also worth carrying out an intercomparison of HER2 and
EGFR data in cohorts of patients from geographical areas where
the incidence of squamous cell carcinoma is high (Japan, China,
France or other countries) obtained by strictly using the same
methodology to eventually highlight a difference of status in
relation with the origin of patients and their food habits. Her-2
status is generally determined by FISH and immunohisto-
chemistry. To our opinion, the serum HER2 is worth being
analysed. Indeed, we reported at the ASCO GI 2006 symposium
preliminary results about HER2, EGF, P53, VEGF and IL6 analysed
by ELISA in the serum of patients treated by radiochemotherapy
for oesophageal squamous cell carcinoma: pretherapeutic serum
HER2 and serum EGF levels seemed to be strongly correlated
(P¼0.017). Moreover, serum HER2 levels suggested an association
with progression (P¼0.059) and metastatic status (P¼0.006); but
only pretherapeutic serum EGF levels were associated with overall
survival (P¼0.046) (Metges et al, 2006).
In conclusion, we think that HER2 is a potentially interesting
target in oesophageal neoplasms. According to Mimura, Hercep-
test 3þ patients are the best candidates for anti-Her2 immune
targeting; this subgroup of patients represents a relatively low
proportion of the total population of oesophageal squamous cell
carcinoma (Mimura et al, 2005b). However, further investigations
needed to confirm these data. Prospective and homogenous series
of patients required to analyse the potential interest of HER2 status
by immunochemistry, serum analysis and gene amplification in
the clinical course of patients with oesophageal squamous cell
carcinoma.
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